Northwestern Events Calendar


INVOForward Therapeutics | Bringing A Drug To Market: Keeping The End In Mind

When: Friday, February 10, 2023
11:00 AM - 11:45 AM CT

Where: Online

Audience: Faculty/Staff - Post Docs/Docs - Graduate Students

Contact: Sonia Kim   (847) 467-0446

Group: Innovation and New Ventures Office

Category: Training


Please join us for the fifth INVOForward seminar during which Stevin Zorn (President & CEO, MindImmune Therapeutics) will cover the following topics:

- Why are medicines valued
- Pharmaceutical Product cycle: high risk but high return
- The roadmaps, risk mitigation & challenges to a new medicine
- Identifying the main resources that will be required across different stages
- ROI, manufacturing, regulatory and reimbursement considerations

This seminar is part of the INVOForward Therapeutics lecture series focused on helping Northwestern researchers gain insight into how to build a compelling therapeutic data package. While the INVOForward mentorship program has four select faculty-led teams participating, the lectures are open to Northwestern Faculty, Post-docs, Staff and Students.

Please register in advance.

Other INVOForward lectures may be found here.


Stevin Zorn, Ph.D.

Stevin Zorn is currently Founder, President, and CEO of MindImmune Therapeutics Inc., a company targeting the immune system to treat diseases of the central nervous system; Ryan Research Professor of Neuroscience, at the George and Anne Ryan Institute for Neuroscience, and adjunct Full Professor of Biomedical and Pharmaceutical Sciences at the College of Pharmacy both at the University of RI; and President of SH Zorn Consulting LLC, a company specializing in Neuroscience pharmaceutical industry consulting. Previously, he was Executive Scientist in Residence and member of the board of directors at Lundbeck USA, and Executive VP of Neuroscience/ site head/ board member for Lundbeck Research USA. Prior to that Dr. Zorn was Vice President and Global Therapeutic Area Head for Central Nervous System Disorders Research Pfizer Global Research and Development in Groton, CT. He held positions including head of General Pharmacology, Alzheimer’s Disease Clinical Development Team Leader, Head of Psychotherapeutics Biology, and Head of Neuroscience Therapeutics. At Pfizer’s Ann Arbor, MI site, Dr. Zorn was a member of the Discovery Research Management Team where he was jointly accountable for site deliverables from 5 therapeutic areas: Neuroscience, Cardiovascular, Inflammation, Dermatology and Infectious Diseases. Dr. Zorn received a BS degree in Chemistry from Lafayette College, Easton, PA, and MS and Ph.D. degrees in Neurotoxicology and Neuropharmacology, respectively, from the University of Texas Graduate School of Biomedical Sciences, Houston, TX. Subsequent postdoctoral research studies centered on basic research of brain and intracellular neuronal signaling mechanisms at the Rockefeller University, New York, NY, in Paul Greengard’s, (Nobel Laureate) laboratory of Molecular and Cellular Neuroscience. 

Dr. Zorn has more than 30 years of drug discovery and drug development experience across a broad range of neuropsychiatric disorders and across the whole value chain for drug discovery and development. His research focus is to discover meaningful treatments to relieve suffering from both Psychiatric and Neurological diseases and to discover breakthrough therapies for Psycho-Neurological diseases. He is an accomplished drug hunter, talented executive leader and mentor with broad pharmaceutical industry knowledge and experience at two major CNS Drug companies and also in biotech. Zorn has mentored dozens of graduate neuroscience students and successful managers and executives in the pharmaceutical industry. Dr. Zorn has been teaching throughout his career both at the undergraduate and graduate levels at various universities, and has mentored dozens of graduate students and industry executives. He has co-authored over 100 scientific research communications and patents and has contributed to the advancement of a wide variety of drug candidates into clinical development. Several of these candidates, including the antipsychotic drug Geodon, which Dr. Zorn played a seminal role in discovering and developing, are now in clinical use helping to improve the lives of millions of patients suffering from CNS -related illnesses around the world.

INVOForward Therapeutics is a 7-week Northwestern mentorship program designed to accelerate biomedical commercialization at the university.

If you have any questions, please email


Register More Info Add to Calendar

Add Event To My Group:

Please sign-in